Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | CBX7 | O95931 | 1/20 | 0.35 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.35 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7887118 | 0.77 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4961767 | 0.69 | SLC6A4 (0.54) | ALDH1A1SMN1; SMN2CDYLADAMTS5CBX7 | |
| SCHEMBL9091776 | 0.69 | RARA (0.51) | ALDH1A1SMN1; SMN2CDYLADAMTS5CBX7 | |
| SCHEMBL2877376 | 0.69 | PDK2 (0.44) | ALDH1A1KDM4EOPRM1OPRK1OPRL1 | |
| SCHEMBL13041624 | 0.69 | C5AR1 (0.47) | ALDH1A1OPRM1OPRK1OPRL1 | |
| SCHEMBL12769743 | 0.68 | KMT2A (0.43) | ALDH1A1SMN1; SMN2CDYLKDM4EADAMTS5 | |
| SCHEMBL13041626 | 0.68 | OPRM1 (0.39) | ALDH1A1SMN1; SMN2CYP2D6CYP2C9OPRM1 | |
| SCHEMBL19699828 | 0.67 | SLC6A4 (0.49) | ALDH1A1SMN1; SMN2CDYLADAMTS5CBX7 | |
| SCHEMBL13041646 | 0.65 | MAPK1 (0.47) | ALDH1A1 | |
| SCHEMBL14169854 | 0.65 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2CDYLKDM4EADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | ALDH1A1 2596/4885SMN1; SMN2 48/4885CDYL 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.